Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes

    ... The efficacy and tolerance of azacitidine in higher-risk myelodysplasia with hypocellular ... the overall survival (OS) advantage demonstrated with azacitidine versus conventional care regimens (CCR). Baseline BM biopsies of ...

    Research Article last updated 02/04/2014 - 1:32pm.

  2. MDS Follows Two Misdiagnoses

    ... erythropoietin (Procrit®), G-CSF, (Neupogen®), azacitidine , (Vidaza®) and deferoxamine (Desferal®). My hemoglobin ... so far this year which is more than usual for me and my last azacitidine (Vidaza®) treatment in June didn't seem to have much benefit. ...

    Patient Chronicle last updated 12/27/2016 - 7:23am.

  3. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

    ... June 4, 2013 Azacitidine is recommended for patients with higher-risk ... to other therapies. However, standard treatment with azacitidine has not been optimized and many issues about the use of azacitidine ...

    Research Article last updated 07/09/2013 - 3:03pm.

  4. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

    ... aimed to directly compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic ... to leukaemic transformation, and adverse outcomes between azacitidine and decitabine. To minimize the effects of treatment selection bias ...

    Research Article last updated 03/05/2013 - 9:07am.

  5. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... The cytidine nucleoside analogue and epigenetic modifier azacitidine is approved in the U.S. for the treatment of all ... to the World Health Organization classification. Benefits of azacitidine treatment of patients with AML with >30% blasts have also been ...

    Research Article last updated 12/09/2015 - 8:49am.

  6. Patients with Myelodysplastic Syndromes Treated with Azacitidine in Clinical Practice: The AVIDA® Registry

    ... ABSTRACT The AVIDA registry evaluated azacitidine usage and effectiveness in unselected MDS patients in ... with previous reports. The AVIDA registry data support azacitidine effectiveness and safety in lower- or higher-risk MDS patients ...

    Research Article last updated 07/07/2014 - 9:42am.

  7. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

    ... clinical or molecular predictors of benefit from azacitidine therapy in patients with myelodysplastic syndromes ... of platelet count at start of second cycle of azacitidine therapy compared to baseline was associated with achieving ... between platelet count doubling after first cycle of azacitidine therapy and probability of achieving objective response. Among ...

    Research Article last updated 08/04/2014 - 8:37am.

  8. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

    ... We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined ... bone marrow blasts . Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days ...

    Research Article last updated 05/22/2014 - 9:28am.

  9. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

    ... and response. Treatment consisted on a combination of azacitidine and vorinostat. Thirty patients (16 with MDS, 14 with AML) were ... the study and treated 79 additional patients: 27 with azacitidine (AZA) and 52 with azacitidine and vorinostat (AZA+V). Median ...

    Research Article last updated 11/28/2016 - 11:15am.

  10. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)

    ... , alone or in combination with ESAs; oral azacitidine ; and new molecules such as the activin receptor type II ligand ...

    Research Article last updated 12/09/2016 - 2:50pm.